Developmental and behavioral consequences of prenatal fluoxetine

Area of Science:

• Neuroscience
• Developmental Psychology
• Pharmacology

Background:

• Selective serotonin reuptuptake inhibitors (SSRIs) like fluoxetine are commonly used antidepressants during pregnancy.
• Research on prenatal fluoxetine primarily focuses on structural teratogenic effects, with less attention to behavioral outcomes.

Purpose of the Study:

• To investigate the postnatal behavioral effects of prenatal fluoxetine exposure in an albino rat model.
• To assess potential impacts on motor development, learning, and memory.

Main Methods:

• Pregnant rats received fluoxetine (8 and 12 mg/kg) or placebo orally from day 6 to 20 of gestation.
• Offspring underwent a battery of behavioral tests post-weaning (day 21), including negative geotaxis, open field, rota-rod, elevated plus maze, and passive avoidance.

Main Results:

• Prenatal fluoxetine exposure did not alter gestational length or cause premature birth/miscarriage.
• High-dose prenatal fluoxetine reduced offspring birth weight and preweaning weight gain, but no major congenital abnormalities were observed.
• A transient delay in motor development was noted, but learning and memory appeared enhanced in specific tests (water maze, passive avoidance).

Conclusions:

• Prenatal fluoxetine exposure in rats results in a temporary motor development delay.
• Despite transient effects on motor activity, prenatal fluoxetine does not produce lasting adverse postnatal behavioral consequences and may enhance certain cognitive functions.